



如何通过Embase获取全面精准的医学和药学信息

——全球最权威的生物医学和药理学数据库

刘 佳

爱思唯尔生命科学资深解决方案经理

133 0107 0662


E.Liu.1@Elsevier.com

励德·爱思唯尔（励讯集团） RELX Group



- 世界最大的科技、医学、法律及商业信息服务供应商
- 财富世界500强企业；英国富时指数排名第20
- 2015年销售收入近90亿美元
- 市值360亿美元
- 40个国家和地区设有250个办公室；客户遍布100个国家和地区
- 85%的收入来自数字化及面对面的商业模式
- 近30000名员工，其中7000名为技术人员

内容介绍



- Embase数据库涵盖的内容和索引体系
- 如何全面和精准的检索药物和疾病信息
- Embase支持循证医学系统评价研究
- Embase支持药物不良反应、药物警戒研究
- Q&A

Embase全球最权威的生物医学和药理学数据库

《荷兰医学文摘》

Embase

收录超过8,200期刊 / 3,500万条文献记录!

其中超过 3,000
种期刊在Medline
未收录

包含100%的MEDLINE内容*



对药物、疾病和
医疗器械进行深
度索引，主题性
检索词是
MEDLINE的
两倍之多(*2.7)



强大的检索功
能和过滤器，
帮助精确查找
最相关的结果



独特的信息管理
功能帮助研究人
员储存和修改复
杂的检索策略，
并可以和其他研
究人员分享检索
策略





独有的超过240万
条会议摘要，自
2009年开始已经收
录超过9000个会议
期刊的文摘



涵盖更多
非英语类文献

Embase将在2019年收录全部PubMed内容和Emcare数据库以及新增6000条中医药词表



Embase 收录的文献学科领域:



其他学科28%
 Including public health, basic biomedical MEDLINE 包含
 公共卫生、基础生物医学以及Medline包含的学科领域

完全涵盖同行评审的生物医学期刊和会议

Embase涵盖更为全面的ADR记录



和MEDLINE相比，Embase涵盖更多非英文类内容


文献收录情况（以2016年为例）

Language	Embase (per year)	MEDLINE (per year)	Unique in Embase
English **	1,413,745	623,018	790,727
Chinese	23,798	13,675	10,123
French	12,094	6,170	5,924
Spanish	12,333	4,273	8,060
Japanese	6,703	5,010	1,693
German	5,522	3,979	1,543
Italian	1,712	982	730
Russian	1,534	421	1,113
Portuguese	364	146	360

随机对照试验收录情况（以2016年为例）

Language	Embase .com	MEDLINE (PubMed)	Embase Advantage	Percentage
Chinese	11042	7427	3615	49%
French	3384	2876	508	18%
Spanish	2876	2128	748	35%
Japanese	2139	1237	902	73%
Russian	2018	1923	95	5%
Polish	575	376	199	53%
Turkish	944	109	835	76%
Korean	193	83	110	13%

10种不同药物在PubMed和Embase种检索记录



Emtree生命科学辞典

生命科学辞典，对生物医学文献进行主题分析、标引和检索时使用的权威性词表。

便于检索

- 超过75,000 个主题词汇以及超过 290,000个同义词汇

海量的药物以及医疗设备检索

- 化学名，商品名，实验室/研发代码，以及超过31,000个药物和化合物首选词汇（FDA, EMA and WHO）
- 超过3,000个设备和医疗设备专属词汇（e.g. endoscopes, catheters, prostheses）以及数千个医疗过程相关词汇（e.g. endoscopy, catheterization）

实时更新


- 每年3次更新最新的药物，疾病，生物体以及医疗过程的索引；包括所有的FDA以及EMA记录的药物名称和WHO从2000起记录的所有国际非专利名称（INNS）。

包含词汇


- 包括所有的MeSH词汇，并且与超过23,000个CAS号进行了链接

Emtree生命科学辞典

对生物医学文献进行主题分析
标引和检索时使用的权威性词表。



- 解剖学概念
- 生物学功能
- 生物医学学科，科学和艺术
- 化学、物理和数学现象
- 化学和药物
- 疾病
- 地理名称
- 按照性别和年龄分组
- 卫生保健概念
- 人群分组
- 生物体/有机体
- 程序，参数和仪器
- 社会与环境
- 文章或研究的类型



History

This term was added to Emtree in 2000

Synonyms

4 [4 (methylsulfonyl) phenyl] 3 phenylfuran 2 (5h) one; alfof; ceox; dolib; mk 0966; mk 966; mk0966; mk966; refo; rhuma-cure; rofetab; rofiz gel; sivoz; toroxx mt; versatil; vioxx; vioxx forte; zyrof

CAS Registry Numbers

[162011-90-7](#); [186912-82-3](#)

Dorland's dictionary

rofecoxib = a nonsteroidal antiinflammatory drug of the COX-2 inhibitors group, used in treatment of osteoarthritis, acute pain, and dysmenorrhea; administered orally.

Vioxx = trademark for a preparation of rofecoxib.

Definition from *Dorland's Medical Dictionary*, 32nd edition, copyright © 2011 by Elsevier. For more information please go to www.dorlands.com

Development of Traditional Chinese Medicine

Taxonomy for Embase



Ruixue Hu¹, Xun Li¹, Xiaoli Li², Femke Mensonides³, Ivan Krstic³, Jianping Liu¹, Yutong Fei*¹

1. Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine

2. School of humanities, Beijing University of Chinese Medicine


3. Embase, Elsevier Information Systems GmbH, Frankfurt, Germany

mtree补充的中医术语体系_与WHO标注术语中中医药术语一致

中医基础理论

中医诊断学

中医疾病



治则治法

针灸


中药和方剂

中医经典

Embase被众多国际性标准制定机构、研究机构和药品监管机构推荐



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



NICE National Institute for
Health and Care Excellence



(cFDA Drug Evaluation Guideline, draft)
药品文献评价指导原则（征求意见稿）
国家食品药品监督管理局药品评价中心

Embase mapping options

'non small cell lung cancer'

[Search >](#) [Mapping ^](#) [Date v](#) [Sources v](#) [Fields v](#) [Quick limits v](#) [EBM v](#) [Pub. types v](#) [Languages v](#) [Gender v](#) [Age v](#) [Animal v](#)

Embase mapping options

[Clear page selections](#) [Col](#)

- Map to preferred term in Emtree
- Search also as free text in all fields
- Explode using narrower Emtree terms
- Search as broadly as possible
- Limit to terms indexed in article as 'major focus'

<input type="checkbox"/>	#4	'non small cell lung cancer'/mj	65,965
<input type="checkbox"/>	#3	'non small cell lung cancer'/exp OR 'non small cell lung cancer'	134,749
<input type="checkbox"/>	#2	'non small cell lung cancer'/exp	129,066
<input type="checkbox"/>	#1	'non small cell lung cancer'/de	101,888

Embase mapping options

'non small cell lung cancer'

[Search >](#) [Mapping ^](#) [Date v](#) [Sources v](#) [Fields v](#) [Quick limits v](#) [EBM v](#) [Pub. types v](#) [Languages v](#) [Gender v](#) [Age v](#) [Animal v](#)

Embase mapping options

[Clear page selections](#) [Col](#)

- Map to preferred term in Emtree
 - Search also as free text in all fields
 - Explode using narrower Emtree terms
 - Search as broadly as possible
- Limit to terms indexed in article as 'major focus'

<input type="checkbox"/>	#4	'non small cell lung cancer'/mj	65,965
<input type="checkbox"/>	#3	'non small cell lung cancer'/exp OR 'non small cell lung cancer'	134,749
<input type="checkbox"/>	#2	'non small cell lung cancer'/exp	129,066
<input type="checkbox"/>	#1	'non small cell lung cancer'/de	101,888

Embase mapping options

'non small cell lung cancer'

[Search >](#) [Mapping ^](#) [Date v](#) [Sources v](#) [Fields v](#) [Quick limits v](#) [EBM v](#) [Pub. types v](#) [Languages v](#) [Gender v](#) [Age v](#) [Animal v](#)

Embase mapping options

[Clear page selections](#)

[Col](#)

- Map to preferred term in Emtree
- Search also as free text in all fields
- Explode using narrower Emtree terms
- Search as broadly as possible
- Limit to terms indexed in article as 'major focus'

<input type="checkbox"/>	#4	'non small cell lung cancer'/mj	65,965
<input type="checkbox"/>	#3	'non small cell lung cancer'/exp OR 'non small cell lung cancer'	134,749
<input type="checkbox"/>	#2	'non small cell lung cancer'/exp	129,066
<input type="checkbox"/>	#1	'non small cell lung cancer'/de	101,888

Embase mapping options

'non small cell lung cancer'

Search >

Mapping ^

Date v

Sources v

Fields v

Quick limits v

EBM v

Pub. types v

Languages v

Gender v

Age v

Animal v

Embase mapping options

Clear page selections

Colla

- Map to preferred term in Emtree
- Search also as free text in all fields
- Explode using narrower Emtree terms
- Search as broadly as possible
- Limit to terms indexed in article as 'major focus'

<input type="checkbox"/>	#4	'non small cell lung cancer'/mj	65,965
<input type="checkbox"/>	#3	'non small cell lung cancer'/exp OR 'non small cell lung cancer'	134,749
<input type="checkbox"/>	#2	'non small cell lung cancer'/exp	129,066
<input type="checkbox"/>	#1	'non small cell lung cancer'/de	101,888

Quick Search

选择语言 | ▼

Quick PICO PV Wizard Advanced Drug Disease Device Article Authors

[Search tips](#)

Quick search ▼

'non small cell lung cancer' ✕

+ Add search field ↻ Reset form

Show 134,749 results >

Limit to:

Publication years (including):

2018 ▼ to 2018 ▼

Records added to Embase (including end date):

1-1-2016 to 31-12-2016 📅

Evidence Based Medicine

- Cochrane Review
- Systematic Review
- Meta Analysis
- Controlled Clinical Trial
- Randomized Controlled Trial

ell lung cancer'/exp OR 'non small cell lung cancer'

Mapping ▾ Date ▾ Sources ▾ Fields ▾ Quick limits ▾ EBM ▾ Pub. types ▾ Languages ▾ Gender ▾ Age ▾ Animal ▾

Se

Filters

— Collapse all

Apply >



Subheadings



es



on types



Search tips

Boolean operators

AND	depression AND tricyclic	Both words or phrases must be present in the record
OR	elderly OR geriatric OR aged	At least one word or phrase must be present in the record
NOT	depression NOT tricyclic	The word phrase before the NOT must be present in the record; the word or phrase after the NOT must be excluded

You can **combine Boolean operators** and use parentheses to create more complex single *search* statements.

(aged **OR** elderly **OR** geriatric) **AND** (depression **OR** insomnia)

Proximity operators

NEAR/n	drug* NEAR/2 adverse	The words must be within n words inclusive of each other in the record
NEXT/n	adverse NEXT/2 reaction*	The words must be within n words inclusive of each other in the same order as they appear in the <i>search</i> form

You can **combine proximity and Boolean operators** and use parentheses to create more complex single *search*.

clinical **NEXT/2** (application* **OR** trial) **NEAR/10** biomarker* **NEAR/10** (treatment **OR** disease)



(adverse **OR** side **OR** undesirable) **NEXT/2** (effect* **OR** reaction* **OR** event* **OR** outcome*)

Pluim D., Ros W., van Bussel M.T.J., Brandsma D., Beijnen J.H., Schellens J.H.M.
Journal of Pharmaceutical and Biomedical Analysis 2019 164 (128-134) Cited by: 0

Embase [Abstract](#) [Index Terms](#) [View Full Text](#)

Similar records

Emtree词表





Embase支持循证医学系统评价研究

文本信息检索是循证医学其中一项重要的步骤




“循证医学，是认真、明确和明智地应用现有的最好证据、结合医生的个人专业技能和临床经验、考虑患者的愿望， 并对患者作出医疗决策。”

- ▶ 提高诊断的准确性，及早发现和预防疾病
- ▶ 应用有疗效的措施，帮助正确合理的治疗疾病
- ▶ 合理用药和促进卫生管理及决策科学化
- ▶ 减少不必要的开支、节约资源

“循证医学能促进临床医疗决策科学化，提高疾病治疗质量，促进临床医学发展。”

循证医学：长期的循证实践的医学过程




此前所有、当前最佳

真实、可靠、适用

与时俱进

1. 选择关键词
2. 构建搜寻指令
3. 查找文献
4. 判断证据等级




阅读全文
 连接 ScienceDirect
 The Cochrane Library

文献管理、注释、分享
 连接 EndNote、Quosa

找到最佳的证据

系统评价是什么？

以某一具体临床问题为基础，系统、全面地收集全世界所有已发表或未发表的临床研究结果，采用临床流行病学严格评价文献的原则和方法，筛选出符合质量标准的文献，进行定性或定量合成，得出综合可靠的结论，并随着新的临床研究的出现及时更新。



*“The systematic review provides a verdict on unsettled medical debates based on a painstaking reassessment of all the relevant research... **the impact can be enormous**. Official guidelines and “best practices” are established or changed after systematic reviews. **Legal standards defining malpractice may be set**; insurers may decide **which treatments to pay for** and which to decline”.*

系统评价领域中具有代表性的就是 Cochrane 和 Joanna Briggs Institute (JBI)

Joanna Briggs Institute (JBI)



THE JOANNA BRIGGS INSTITUTE

Cochrane Database of Systematic Reviews



Journals that publish SRs (Top 10 articles in Embase.com)

Journal title	No.	Impact Factor '1
Cochrane Database of Systematic Reviews	16750	6.124
PLoS ONE	3256	2.806
Value in Health	2332	4.491
BMJ Open	908	2.369
Medicine (United States)	889	1.803
Chinese Journal of Evidence-Based Medicine 中国循证医学杂志	825	1.098
Journal of Clinical Oncology	771	24.008
JBI Database of Systematic Reviews and Implementation Reports	766	0.21
Oncotarget	635	5.168
Gastroenterology	607	18.187

系统评价的基础上目前流行的应用_临床实践指南

based on a **systematic evidence review**, developed by panel of multidisciplinary experts, provide a clear explanation of the logical relationships between alternative care options and health outcomes, and provide ratings of both the quality of evidence and the strength of the recommendations

- Tell clinicians how to practice
- Published by national and international authority
- Favoured by health care systems

Example:

Home > NICE Guidance > Conditions and diseases > Cancer > Lung cancer

Lung cancer: diagnosis and management

Clinical guideline [CG121] Published date: April 2011 [Uptake of this guidance](#)

Recommendations

This guideline includes recommendations on:

- [access to services and referral](#)
- [communication](#)
- [diagnosis and staging](#)
- [treatment](#)
- [palliative interventions and supportive and palliative care](#)
- [follow-up and patient perspectives](#)

Who is it for?

- Healthcare professionals
- People with lung cancer and their families and carers

临床实践指南

中国临床肿瘤学会(CSCO)原发性肺癌诊疗指南 2016.V1

中国临床肿瘤学会指南工作委员会
 执笔: 吴一龙 程颖 周清 林冬梅 王洁 王长利 王绿化
 卢轴 陆舜 周彩存 黄诚 宋启斌 钟文昭

前言

基于循证医学证据和精准医学基本原则制定中国原发性肺癌的诊断和治疗指南

是中国临床肿瘤学
 了一个新的趋势
 导性显著的国家
 CO 指南必须兼顾
 价值三方面。因此
 分为基本策略和
 留治疗价值相对
 控或性价比超出
 已批准上市但我
 南工作委员会相
 们期待大家的反

影像和分期
 病理学诊断
 分子分型
 基于病理类型
 随访
 附件

The screenshot shows the official website of the National Health Commission of the People's Republic of China. The page title is '中国居民口腔健康指南' (China Oral Health Guidelines), published on 2009-09-15. The content includes an introduction to oral health as a key part of the human body and digestive system, and a list of factors that can interfere with oral health. The page also features a search bar and a navigation menu with categories like '首页', '机构职能', '新闻中心', '政务公开', '政务服务', '交流互动', and '专题专栏'.

指南的制定遵循循证医学

应用步骤


1. 提出问题
2. 用恰当的主题词 (关键词、自由词) 检索获取证据
3. 对指南的质量进行评价
4. 审视指南是否回答临床所解决的问题
5. 应用证据和指南
6. 最后进行后效评价

Health Technology Assessment / 医药技术经济学评估

systematic evaluation of properties, effects, and/or impacts of **health technology**, provided by an independent agency. The purpose is to Inform policymaking for technology in health care.

- Regulatory agencies about whether to permit the commercial use of a drug, device or other regulated technology
- Payers (health care authorities, health plans etc.) about technology coverage, coding (assigning proper codes to enable reimbursement), and reimbursement (how much to pay)
- Standards-setting organizations for health technology and health care delivery
- Government health department officials about undertaking public health programs (e.g., immunization, screening, and environmental protection programs)

如何撰写一份符合具有高标准和质量的系统评价



系统评价的最终成果

TABLE OF CONTENTS

HEADER	
ABSTRACT	
PLAIN LANGUAGE SUMMARY	
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	
BACKGROUND	
OBJECTIVES	
METHODS	7
RESULTS	
Figure 1.	
Figure 2.	
Figure 3.	
ADDITIONAL SUMMARY OF FINDINGS	18
DISCUSSION	20
AUTHORS' CONCLUSIONS	20
ACKNOWLEDGEMENTS	20
REFERENCES	20
CHARACTERISTICS OF STUDIES	24
DATA AND ANALYSES	37
CONTRIBUTIONS OF AUTHORS	37
DECLARATIONS OF INTEREST	37
SOURCES OF SUPPORT	37
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	38

- Criteria for considering studies for this review
- Search methods for identification of studies
- Data collection and analysis



Cochrane Library
Cochrane Database of Systematic Reviews


Topical anaesthesia for needle-related pain in newborn infants (Review)

Foster JP, Taylor C, Spence K

系统评价的方法和步骤

Cochrane干预措施系统评价手册 规定的制作系统评价的八个步骤:

1. 提出要评价的问题，制定纳入研究的标准
2. 检索研究
3. 筛选研究和收集数据
4. 评估纳入研究的偏倚风险
5. 分析数据并进行Meta分析
6. 解决报告偏倚
7. 陈述结果与制作结果摘要表格
8. 解释结果与得出结论



Cochrane 干预措施系统评价手册
中文翻译版
2014.12.1

系统评价的方法和步骤

Cochrane干预措施系统评价手册 规定的制作系统评价的八个步骤:

1. 提出要评价的问题，制定纳入研究的标准

2. 检索研究

3. 筛选研究和收集数据

4. 评估纳入研究的偏倚风险

5. 分析数据并进行Meta分析

6. 解决报告偏倚

7. 陈述结果与制作结果摘要表格

8. 解释结果与得出结论

- 系统评价问题应指明人群（研究对象）类型，干预措施（和对照措施）类型，以及所关注的结局类型。为便于记忆简称**PICO**，即**研究对象（Participants）**，**干预措施（Interventions）**，**对照措施（Comparisons）**，和**结局（Outcomes）**。
- 这些问题的要素，以及对纳入研究类型的规定构成了系统评价预先设定的纳入标准的基础。

系统评价的方法和步骤

Cochrane干预措施系统评价手册 规定的制作系统评价的八个步骤:

1. 提出要评价的问题，制定纳入研究的标准

2. 检索研究

3. 筛选研究和收集数据

4. 评估纳入研究的偏倚风险

5. 分析数据并进行Meta分析


6. 解决报告偏倚

7. 陈述结果与制作结果摘要表格

8. 解释结果与得出结论

- 临床试验注册库和试验结果注册库逐渐成为重要的信息源。
- 所有Cochrane系统评价应检索Cochrane中心对照试验注册库（**CENTRAL**）、**MEDLINE**和**EMBASE**（如果系统评价作者或TSC能进入上述数据库），这些检索或是直接检索，或是通过CRG的专业注册库。


系统评价手册



Cochrane 干预措施系统评价手册 中文翻译版



系统评价指导手册 (2010)
杨克虎 (作者, 编者)



中西医结合诊疗指南制定手
册 (2016)
卢传坚, 杨克虎 (作者)



全国高等学校循证医学类
教材:循证临床实践指南的
制定与实施 (2016)
王小钦, 王吉耀 (编者)

Embase的系统评价检索表单，融入PICO4大要素

PICO – Population, Patient, Problem



PICO - Intervention



PICO - Comparison




PICO - Outcome



Embase的系统评价检索表单，融入PICO4大要素

- **P** = Patient (人群)
- **I** = Intervention (干预措施)
- **C** = Comparison/control (对照措施)
- **O** = Outcome (结果)

这些问题的要素的交集，构成了系统评价预先设定的纳入标准的基础



PICOS案例

Interventions for treating oral leukoplakia to prevent oral cancer

TABLE OF CONTENTS

HEADER		1
ABSTRACT		1
PLAIN LANGUAGE SUMMARY		2
SUMMARY OF FINDINGS FOR THE MAIN CO		4
BACKGROUND		6
OBJECTIVES		7
METHODS		7
RESULTS		11
Figure 1.		12
Figure 2.		14
Figure 3.		15
ADDITIONAL SUMMARY OF FINDINGS		18
DISCUSSION		20
AUTHORS' CONCLUSIONS		20
ACKNOWLEDGEMENTS		20
REFERENCES		20
CHARACTERISTICS OF STUDIES		24
DATA AND ANALYSES		37
CONTRIBUTIONS OF AUTHORS		37
DECLARATIONS OF INTEREST		37
SOURCES OF SUPPORT		37
DIFFERENCES BETWEEN PROTOCOL AND		38

Types of interventions

Active

- Surgical removal of the lesion, including surgical excision, laser surgery, cryotherapy
- Systemic medical treatment
- Topical medical treatment, including anti-inflammatory agents, antimicrobial agents, corticosteroids and retinoids, cytotoxic agents, etc.
- Removal of predisposing habits (e.g. tobacco, alcohol)
- Other treatment (e.g. photodynamic therapy)

Control

- Continued treatment
- Placebo
- No treatment

Types of outcome measures

In light of the pre-cancerous nature of leukoplakia, the primary objective of treatment is to prevent cancer development.

Primary outcomes

- Oral cancer development, demonstrated by histopathological examination

Secondary outcomes

- Clinical resolution, in terms of the proportion of lesions that did not receive birth-reuse data when provided
- Improvement of histological features, in terms of the proportion of lesions that did not show improvement in histological features
- Safety of the intervention, as measured by the incidence of adverse effects

Electronic searches

We searched the following databases.

- Cochrane Oral Health's Trials Register (to 16 May 2016) (see Appendix 2);
- The Cochrane Central Register of Controlled Trials (CENTRAL) (*the Cochrane Library*; 2016, Issue 4) (see Appendix 3);
- MEDLINE Ovid (1946 to 16 May 2016) (see Appendix 1);
- Embase Ovid (1980 to 16 May 2016) (see Appendix 4);
- CancerLit via PubMed (1950 to 16 May 2016) (see Appendix 5).

We placed no restrictions on the language or date of publication when searching the electronic databases.

Searching other resources

We searched the following databases for ongoing trials (see Appendix 6 for details of the search strategy).

- metaRegister of Controlled Trials [↗](#) (to 10 February 2015);
- ClinicalTrials.gov [↗](#) (to 16 May 2016);
- The WHO International Clinical Trials Registry Platform [↗](#) (to 16 May 2016).

We manually checked the reference lists of included studies and existing reviews. The metaRegister of Controlled Trials is no longer available and so was not searched in May 2016.

PICOS案例

P	=	Anyone with a diagnosis of oral leukoplakia	e.g. 'oral leukoplakia'/exp OR 'oral leukoplakia' OR (oral AND ('leukoplakia'/exp OR leukoplakia))'
I	=	NSAIDS or bowman birk inhibitor	e.g. 'nonsteroid antiinflammatory agent'/exp OR 'nonsteroid antiinflammatory agent' OR 'bowman birk inhibitor'/exp OR 'bowman birk inhibitor' OR
C	=	no treatment or placebo	e.g. 'placebo'/exp OR 'placebo' OR 'placebo gel' OR 'placebos'
O	=	cancer prevention	e.g. 'cancer prevention'/exp

PICO检索

Search



PICO PV Wizard Advanced Drug Disease Device Article Authors

- synyms
- nia
- ALL
- sis nicotinic paltina
- mouth
- oral
- sis
- sis nicotinic paltina
- mouth
- oral
- oplakia
- oplakia
- e lesion
- precancerous
- remalignant

Default search

/mj /de /ex

Population

leukoplakia /exp + 23 synonyms :all

Intervention

e.g. insulin

Comparison

e.g. placebo

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 9,098 r

PICO检索

Search



PICO PV Wizard Advanced Drug Disease Device Article Authors

- synonyms
- Bowman Birk inhibitor ALL
- Bowman Birk inhibitor
- Bowman Birk inhibitor
- Bowman Birk inhibitor
- Bowman Birk inhibitor, Bowman Birk soybean
- Bowman Birk inhibitor, Bowman Birk soybean

Default search
/mj /de /ex

Population

leukoplakia /exp

Intervention

Bowman Birk inhibitor /exp + 5 synonyms :all OR nonsteroid antiinflammatory agent /exp + 18 synonyms :all

Comparison

e.g. placebo

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 230 r

PICO检索

Search



PICO PV Wizard Advanced Drug Disease Device Article Authors

onyms



ALL



Default search



Population

leukoplakia /exp

Intervention

Bowman Birk inhibitor /exp + 5 synonyms :all OR nonsteroid antiinflammatory agent /exp

Comparison

placebo /exp + 3 synonyms :all

Outcome

e.g. risk

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 35 r

PICO检索

Search



PICO PV Wizard Advanced Drug Disease Device Article Authors

- ymms
- revention ALL
- ention
- hylaxis
- cancer
- ention
- vention

Default search
/mj /de /ex

Population

leukoplakia /exp

Intervention

Bowman Birk inhibitor /exp + 5 synonyms :all OR nonsteroid antiinflammatory agent /exp

Comparison

placebo /exp

Outcome

cancer prevention /exp + 5 synonyms :all

Study design (or miscellaneous)

e.g. randomized controlled trial

Reset query Info

Show 23 r

History Save | Delete | Print view | Export | Email Combine > using And Or #1 ('leukoplakia'/exp OR 'leucokeratosis nicotinic paltina' OR 'leucoplakia' OR 'leucoplakia, mouth' OR 'leucoplakia, oral' OR 'leukokeratosis' OR 'leukokeratosis nicotinic paltina' OR 'leukoplakia' OR 'leukoplakia, mouth' OR 'leukoplakia, oral' OR 'leukoplasia' OR 'mouth leukoplakia' OR 'mouth leukoplakia' OR 'mouth white lesion' OR 'oral lesion, precancerous' OR 'oral lesion, premalignant' OR 'oral leukoplakia' OR 'oral leukoplakia' OR 'oral precancerous condition' OR 'oral white lesion' OR 'precancerous oral lesion' OR 'precarcinoma, mouth' OR 'pre-malignant oral lesion' OR 'white lesion, mouth') AND ('nonsteroid antiinflammatory agent'/exp OR 'nsaid' OR 'anti inflammatory agents, non steroidal' OR 'anti-inflammatory agents, non-steroidal' OR 'antiinflammatory agent, nonsteroid' OR 'non steroid antiinflammatory agent' OR 'non steroid antiinflammatory drug' OR 'non steroidal anti inflammatory agent' OR 'non steroidal anti inflammatory drug' OR 'non steroidal antiinflammatory agent' OR 'non steroidal antiinflammatory drug' OR 'nonsteroid antiinflammatory agent' OR 'nonsteroid antiinflammatory drug' OR 'nonsteroid antiinflammatory agent' OR 'nonsteroid antiinflammatory drug' OR 'nonsteroid antiinflammatory agent' OR 'nonsteroidal anti inflammatory drug' OR 'nonsteroidal anti inflammatory drugs' OR 'nonsteroidal anti-inflammatory drugs' OR 'nonsteroidal antiinflammatory agent' OR 'nonsteroidal antiinflammatory drug' OR 'bowman birk inhibitor'/exp) AND 'placebo'/exp AND 'cancer prevention'/exp18 results for search #1 [Set email alert](#) [Set RSS feed](#) [Search details](#) [Index miner](#) Results View | Print | Export | Email | Order | Add to Clipboard

Select number of items Selected: 0 (clear)

Show all abstracts | Sort by: Relevance Publication Year Entry Date

- | | |
|----------------------------|--|
| <input type="checkbox"/> 1 | Novel molecular targets for chemoprevention in malignancies of the head and neck
Bhatia A., Burtness B.
<i>Cancers</i> 2017 9:9 Article Number 113 Cited by: 2
Embase Abstract Index Terms View Full Text Similar records |
| <input type="checkbox"/> 2 | Interventions for treating oral leukoplakia to prevent oral cancer
Lodi G., Franchini R., Warnakulasuriya S., Varoni E.M., Sardella A., Kerr A.R., Carrassi A., Macdonald L.C.I., Worthington H.V.
<i>Cochrane Database of Systematic Reviews</i> 2016 2016:7 Article Number CD001829 Cited by: 28
Embase MEDLINE Abstract Index Terms View Full Text Similar records |
| <input type="checkbox"/> 3 | Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory
Dionne K.R., Warnakulasuriya S., Zain R.B., Cheong S.C.
<i>International Journal of Cancer</i> 2015 136:3 (503-515) Cited by: 59
Embase MEDLINE Abstract Index Terms View Full Text Similar records |
| <input type="checkbox"/> 4 | PPAR γ in head and neck cancer prevention
Burotto M., Szabo F. |



Embase支持药物警戒和不良反应

什么是药物警戒？



Pharmacovigilance is all about

adverse drug reactions

药物警戒是一项发现、评价、理解和预防不良反应或其他任何可能与药物有关问题的科学研究与活动。

药物警戒的最终目标为合理、安全地使用药品；对已上市药品进行风险/效益评价和交流；对患者进行培训、教育，并及时反馈相关信息。

Thalidomide 灾难导致药物不良反应监测制度建立



- 1950s Thalidomide被开发用于新型抗菌药物
- 1957年 正式投放欧洲市场，不久进入其他国家市场作为一种“没有任何副作用的抗妊娠反应药物”
- 1961年 在世界各国陆续撤回，因服用反应停而导致的畸形婴儿据保守估计大约有1万人，还有大约5000到7000个婴儿在出生前就已经因畸形死亡

THALIDOMIDE AND CONGENITAL ABNORMALITIES

SIR,—Congenital abnormalities are present in approximately 1.5% of babies. In recent months I have observed a marked increase in the incidence of multiple severe abnormalities in babies delivered of women who were given the drug thalidomide ('Distaval') during pregnancy, as an anti-nausea or as a sedative, to be almost 20%.

These abnormalities are present in structures developed from mesenchyme—i.e., the bones and musculature of the gut. Bony development seems to be affected in a very striking manner, resulting in polydactyly, syndactyly, and failure of development of long bones (abnormally short femora and radii).

Have any of your readers seen similar abnormalities in babies delivered of women who have taken this drug during pregnancy?

Hurstville, New South Wales.

W. G. McBRIDE.

* * * In our issue of Dec. 2 we included a statement from the Distillers Company (Biochemicals) Ltd. referring to "reports from two overseas sources possibly associating thalidomide ('Distaval') with harmful effects on the fetus in early pregnancy". Pending further investigation, the company decided to withdraw from the market all its preparations containing thalidomide.—Ed.L.

美国公众要求国会
加强立法




1962 美国国会通过了
Kefauver-Harris 修正案




1967 WHO 10个国家参加
的国际药物监测合作计划

文献报告：作为药物不良反应数据信息重要来源



Reported adverse events by report source,
Q2 & Q3 2013

N = 34,469 unique events





GVP Module VI 对于文献报告作出详细规定

VI.B.1.1.2. Literature reports

The medical literature is a significant source of information for the monitoring of the **safety profile and of the risk-benefit balance of medicinal products**, particularly in relation to the detection of new safety signals or emerging safety issues. Marketing authorisation holders are therefore expected to maintain awareness of possible publications through a **systematic literature review of widely used reference databases** (e.g. Medline, Excerpta Medica or **Embase**) no less frequently than once a week.

Reports of suspected adverse reactions from the medical literature, including relevant published **abstracts from meetings and draft manuscripts**, should be reviewed and assessed by marketing authorisation holders to identify and record ICSRs.

.....

In addition, marketing authorisation holders should have procedures in place to **monitor scientific and medical publications in local journals** in countries where medicinal products have a marketing authorisation, and to bring them to the attention of the company safety department as appropriate.

VI.B.6. Special situations

Use of a medicinal product during pregnancy or breastfeeding, in a paediatric or elderly population, lack of therapeutic efficacy, overdose, abuse, misuse, medication error or occupational exposure

美国食品药品监督管理局FDA对于人类用药和生物制品包含疫苗的不良反应报告要求

Types of Post-Marketing Adverse Event Data

• Spontaneous/voluntary reporting of cases

- National (FDA MedWatch)
- Local or Regional (Joint Commission Requirement)

- Scientific literature publications

• Post-marketing studies (voluntary or required)

- Observational studies (including automated healthcare databases)
- Randomized clinical trials

• Active surveillance

- Drug-Induced Liver Injury Network (DILIN)
- Sentinel initiative

... serious, unexpected adverse experiences **reported in the scientific literature** (or in an unpublished scientific paper) that are known to the applicant must be submitted as **15-day reports**...


... Applicants can use literature search services (e.g., **Weekly Reactions**) to identify adverse experiences in the scientific literature...

... When a serious, unexpected adverse experience is based on **a foreign language article or manuscript**, the applicant should **translate the publication into English** promptly...



药品文献评价指导原则（征求意见稿）2018.06

- “文献”包括已公开发表的文献、未公开发表的文献（即灰色文献）等。
- “文献评价”是指尽可能全面系统地收集一定时间范围内、特定药品的安全性、有效性研究文献，在对文献进行质量评价、资料提取、归纳整理的基础上，进行综合地分析评价，并形成评价报告的过程。



案例分析：系统、全面的查找药物的临床不良反应

- **背景介绍：**国家食药监总局正式批准百时美施贵宝Opdivo/Nivolumab 用于治疗表皮生长因子受体（EGFR）基因突变阴性和间变性淋巴瘤激酶（ALK）阴性、既往接受过含铂方案化疗后疾病进展或不可耐受的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。
- **目标：**查找全球范围内报告的临床使用不良反应

药品不良反应报告和监测管理办法：进口药品和国产药品在境外发生的严重药品不良反应（包括自发报告系统收集的、**上市后临床研究发现**的、**文献报道**的），药品生产企业应当填写《境外发生的药品不良反应/事件报告表》，自获知之日起30日内报送国家药品不良反应监测中心

常见的检索药物不良反应的组合 – 繁琐复杂，无头绪！

目标是达到100%的召回率（recall），即在数据库中识别出所有和该药物不良反应有关的文献。

'paracetamol'/drug toxicity','drug interaction','adverse drug reaction' OR 'paracetamol-induced':de,ab,ti

OR ('paracetamol':de OR '4 acetamidophenol':tn,ab,ti OR '4 acetaminophenol':tn,ab,ti OR '4 acetylamino phenol':tn,ab,ti OR '4 hydroxyacetanilide':tn,ab,ti OR '4' hydroxyacetanilide':tn,ab,ti OR 'abenol':tn,ab,ti OR 'acamol':tn,ab,ti OR 'acamoli forte suppositories for kids':tn,ab,ti OR 'acanol':tn,ab,ti OR 'acephen':tn,ab,ti OR 'acet suppositories':tn,ab,ti OR 'acetalgin':tn,ab,ti OR 'acetamino phenol':tn,ab,ti OR 'acetaminophen':tn,ab,ti OR 'acetaminophene':tn,ab,ti OR 'acetaminophenol':tn,ab,ti OR 'acetamol':tn,ab,ti OR 'acetomenophen':tn,ab,ti OR 'acetylamino phenol':tn,ab,ti OR 'adorem':tn,ab,ti OR 'afebrin':tn,ab,ti OR 'algiafin':tn,ab,ti OR 'algotropyl':tn,ab,ti OR 'alphagesic':tn,ab,ti OR 'alvedon':tn,ab,ti OR 'amadil':tn,ab,ti OR 'anacin 3':tn,ab,ti OR 'anafion':tn,ab,ti OR 'analgiser':tn,ab,ti OR 'apamide':tn,ab,ti OR 'apap':tn,ab,ti OR 'apirex':tn,ab,ti OR 'apotel':tn,ab,ti OR 'arthralgen':tn,ab,ti OR 'atamel':tn,ab,ti OR 'ben-u-ron':tn,ab,ti OR 'benuron':tn,ab,ti OR 'biogesic':tn,ab,ti OR 'biogesic suspension':tn,ab,ti OR 'bodrex':tn,ab,ti OR 'calapol':tn,ab,ti OR 'calodol':tn,ab,ti OR 'calonal':tn,ab,ti OR 'calpol':tn,ab,ti OR 'causalon':tn,ab,ti OR 'cemol':tn,ab,ti OR 'christamol':tn,ab,ti OR 'claradol':tn,ab,ti OR 'clocephen':tn,ab,ti OR 'cp 500':tn,ab,ti OR 'cp500':tn,ab,ti OR 'dafalgan':tn,ab,ti OR 'daga':tn,ab,ti OR 'datril':tn,ab,ti OR 'depon':tn,ab,ti OR 'depyretin':tn,ab,ti OR 'dirox':tn,ab,ti OR 'dismifen':tn,ab,ti OR 'disprol':tn,ab,ti OR 'dolal':tn,ab,ti OR 'dolex':tn,ab,ti OR 'dolex 500':tn,ab,ti OR 'doliprane':tn,ab,ti OR 'dolitabs':tn,ab,ti OR 'dolofen':tn,ab,ti OR 'dolomol':tn,ab,ti OR 'dolorol':tn,ab,ti OR 'dolotemp':tn,ab,ti OR 'dolprone':tn,ab,ti OR 'doltem':tn,ab,ti OR 'drilan':tn,ab,ti OR 'dristan af':tn,ab,ti OR 'duorol':tn,ab,ti OR 'dymadon':tn,ab,ti OR 'efferalgan':tn,ab,ti OR 'efferalgan 500':tn,ab,ti OR 'efferalganodis':tn,ab,ti OR 'efferelgan':tn,ab,ti OR 'enelfa':tn,ab,ti OR 'eneril':tn,ab,ti OR 'eraldor':tn,ab,ti OR 'expandol':tn,ab,ti OR 'febrilix':tn,ab,ti OR 'fendon':tn,ab,ti OR 'fervex':tn,ab,ti OR 'fibrinol':tn,ab,ti OR 'fortolin':tn,ab,ti OR 'gelocatil':tn,ab,ti OR 'geluprane 500':tn,ab,ti OR 'gunaceta':tn,ab,ti OR 'headache strength allerest':tn,ab,ti OR 'hedex':tn,ab,ti OR 'infants' feverall':tn,ab,ti OR 'injectapap':tn,ab,ti OR 'janupap':tn,ab,ti OR 'kamolas':tn,ab,ti OR 'kyofen':tn,ab,ti OR 'lemgrip':tn,ab,ti OR 'letamol':tn,ab,ti OR 'liquiprin':tn,ab,ti OR 'lotemp':tn,ab,ti OR 'lyteca':tn,ab,ti OR 'malidens':tn,ab,ti OR 'medamol':tn,ab,ti OR 'meforagesic':tn,ab,ti OR 'metagesic':tn,ab,ti OR 'metalid':tn,ab,ti OR 'mexalen':tn,ab,ti OR 'mildon 500':tn,ab,ti OR 'minopan':tn,ab,ti OR 'mypara':tn,ab,ti OR 'n acetyl 4 amino phenol':tn,ab,ti OR 'n acetyl para amino phenol':tn,ab,ti OR 'n-acetyl-p-amino phenol':tn,ab,ti OR 'nalgesik':tn,ab,ti OR 'napamol':tn,ab,ti OR 'napap':tn,ab,ti OR 'naprex':tn,ab,ti OR 'nektol 500':tn,ab,ti OR 'neocitran':tn,ab,ti OR 'neodalmin':tn,ab,ti OR 'neopap':tn,ab,ti OR 'nevral':tn,ab,ti OR 'nilapur':tn,ab,ti OR 'nobedon':tn,ab,ti OR 'nysacetol':tn,ab,ti OR 'ofirmev':tn,ab,ti OR 'pacemol':tn,ab,ti OR 'pacimol':tn,ab,ti OR 'pamal':tn,ab,ti OR 'pamol':tn,ab,ti OR 'panadol':tn,ab,ti OR 'panadol actifast':tn,ab,ti OR 'panadol soluble':tn,ab,ti OR 'panamax':tn,ab,ti OR 'panasorb':tn,ab,ti OR 'panodil':tn,ab,ti OR 'para acetamidophenol':tn,ab,ti OR 'para acetylamino phenol':tn,ab,ti OR 'para hydroxyacetanilide':tn,ab,ti OR 'para suppo':tn,ab,ti OR 'paracet':tn,ab,ti OR 'paracetaminophenol':tn,ab,ti OR 'paracetamol':tn,ab,ti OR 'paracetamol ester':tn,ab,ti OR 'paracetamole':tn,ab,ti OR 'parageniol':tn,ab,ti OR 'paragin':tn,ab,ti OR 'paralen':tn,ab,ti OR 'paralief':tn,ab,ti OR 'paramax':tn,ab,ti OR 'paramidol':tn,ab,ti OR 'parapaed':tn,ab,ti OR 'parapaed junior':tn,ab,ti OR 'parapaed six plus':tn,ab,ti OR 'paratabs':tn,ab,ti OR 'paravid':tn,ab,ti OR 'pasolind':tn,ab,ti OR 'pasolind n':tn,ab,ti OR 'paximol':tn,ab,ti OR 'pedipan':tn,ab,ti OR 'penral-night':tn,ab,ti OR 'perfalgan':tn,ab,ti OR 'phenaphen':tn,ab,ti OR 'pinex':tn,ab,ti OR 'polarfen':tn,ab,ti OR 'predimol':tn,ab,ti OR 'puernol':tn,ab,ti OR 'pyrigesic':tn,ab,ti OR 'raperon':tn,ab,ti OR 'rapidol':tn,ab,ti OR 'relaphen':tn,ab,ti OR 'reliv':tn,ab,ti OR 'remedol':tn,ab,ti OR 'revanin':tn,ab,ti OR 'rhinapen elixir':tn,ab,ti OR 'rhodapap':tn,ab,ti OR 'roxamol gelcaps':tn,ab,ti OR 'salzone':tn,ab,ti OR 'sedes a':tn,ab,ti OR 'serimol':tn,ab,ti OR 'setamol':tn,ab,ti OR 'sinaspril':tn,ab,ti OR 'sinedol':tn,ab,ti OR 'sinpro':tn,ab,ti OR 'tabalgin':tn,ab,ti OR 'tachipirin':tn,ab,ti OR 'tachipirina':tn,ab,ti OR 'taganopain':tn,ab,ti OR 'tapar':tn,ab,ti OR 'tempra':tn,ab,ti OR 'tempte':tn,ab,ti OR 'temzzard':tn,ab,ti OR 'termofren':tn,ab,ti OR 'tralgon':tn,ab,ti OR 'tralgon elixir':tn,ab,ti OR 'tramil':tn,ab,ti OR 'treuphadol':tn,ab,ti OR 'turpan':tn,ab,ti OR 'tylenol':tn,ab,ti OR 'tylenol (caplet)':tn,ab,ti OR 'tylenol (geltab)':tn,ab,ti OR 'tylenol extra fuerte':tn,ab,ti OR 'tylenol forte':tn,ab,ti OR 'tylenol nr 1':tn,ab,ti OR 'tylex':tn,ab,ti OR 'valadol':tn,ab,ti OR 'winadol':tn,ab,ti OR 'winasorb':tn,ab,ti OR 'xebramol':tn,ab,ti OR 'zolben':tn,ab,ti OR 'zydinol':tn,ab,ti

AND ('adverse drug reaction'/exp OR 'adverse drug reaction':lnk OR adverse:de,ab,ti OR ((side OR undesirable OR unwanted) NEXT/2 (effect* OR reaction* OR event* OR outcome*)):de,ab,ti OR 'side effect'/lnk OR 'side effect'/exp OR 'complication'/lnk OR 'complication'/exp OR complication*:de,ab,ti OR 'worsening':de,ab,ti

OR 'case report':de,ab,ti OR 'pharmacovigilance':de,ab,ti OR 'postmarketing surveillance'/exp OR 'drug interaction':lnk OR 'drug interaction'/exp OR 'toxicity'/exp OR 'drug toxicity':lnk OR toxic*:de,ab,ti OR intoxic*:de,ab,ti OR 'safety':de,ab,ti OR poison*:de,ab,ti OR pharmacotox*:de,ab,ti OR neurotox*:de,ab,ti OR cardiotox*:de,ab,ti OR nephrotox*:de,ab,ti OR hepatotox*:de,ab,ti OR immunotox*:de,ab,ti OR immunocytotox*:de,ab,ti OR cytotox*:de,ab,ti OR carcinogen*:de,ab,ti OR cancerogen*:de,ab,ti OR mutagen*:de,ab,ti OR terato*:de,ab,ti OR 'fatal outcome'/exp OR 'death'/exp OR death*:de,ab,ti OR 'suicide'/exp OR suicid*:de,ab,ti OR mortal*:de,ab,ti OR fatal*:de,ab,ti OR 'risk'/exp OR nocebo:de,ab,ti OR 'lethal concentration'/exp OR 'iatrogenic disease'/exp OR 'fertility'/exp OR 'substance-related disorders'/exp OR 'chemically induced':de,ab,ti OR 'morbidity':de,ab,ti OR 'congenital disorder':de,ab,ti OR 'infertility'/exp OR 'injury'/exp


OR 'pregnancy'/exp OR pregnant*:de,ab,ti OR 'pregnanc':de,ab,ti OR 'pregnancy complication'/exp OR 'pregnancy disorder'/exp OR 'abortion'/exp OR 'abortion':de,ab,ti OR 'lactation'/exp OR 'breast feeding':de,ab,ti OR 'breastfeeding':de,ab,ti OR 'breast milk':de,ab,ti OR 'reproduction'/de OR 'fetus'/de OR 'embryo'/de OR 'prenatal':de,ab,ti OR 'perinatal':de,ab,ti OR 'newborn':de,ab,ti OR 'parameters concerning the fetus, newborn and pregnancy'/exp OR aged/exp or elderly:de,ti,ab or geriatric*:ti,ab

OR ((environmental OR occupational) NEXT/1 exposure*):de,ab,ti OR 'compassionate use':de,ab,ti OR (named NEXT/1 (use OR patient*)):ab,ti OR 'inappropriate prescri*':de,ab,ti

OR 'drug metabolism'/exp OR 'organ dysfunction':de,ab,ti OR 'organ failure':de,ab,ti OR 'hypersensitivit*':de,ab,ti OR allerg*:de,ab,ti OR counterfeit:de,ab,ti OR 'falsified drug':de,ab,ti OR ('unavailab*' NEAR/2 drug):de,ab,ti OR 'drug resistance'/exp OR 'drug resistance':de,ab,ti OR 'withdrawal syndrome'/de OR (drug* NEAR/3 (withdrawal OR toleran* OR interact* OR exposure* OR induc* OR resist* OR ineff* OR nonrespon* OR unrespon*)):de,ab,ti OR 'drug tolerance'/exp OR ((drug* OR treatment) NEXT/1 (failure* OR contraindication*)):de,ab,ti OR 'medication error'/exp OR (near NEXT/1 miss*):ab,ti OR ineff*:ti OR nonrespon*:ti OR unrespon*:ti OR ((lack OR no OR non OR 'not') NEXT/2 (eff* OR respon*)):ab,ti OR 'device failure':de,ab,ti OR manufacturing near/3 (error or fault or mistake or failure or contamination or impurity) OR 'patient compliance'/exp OR overdos*:de,ab,ti OR 'drug abuse'/exp OR abus*:de,ab,ti OR misus*:de,ab,ti OR 'off label':de,ab,ti OR 'unlicensed':de,ab,ti)

AND ('human'/exp OR human OR m?n OR wom?n OR child OR boy OR girl))

The fundamentals of PV Wizard framework



Search Summary

Start [Drug] / [Subheading]

OR ([Drug name]

AND ([Adverse drug reac

OR [Special conditions

AND [Human limit]

Embase的专门检索表单PV Wizard

[EMA's MLM searches >](#)

Drug name

Alternative drug names

Adverse drug reactions

Special situations

Human limit

Drug name

opdivo

opdivo use: nivolumab

7,586

Subheadings

- Adverse drug reaction
- Drug toxicity
- Drug interaction
- Drug combination
- Drug comparison
- Drug therapy

Drug name

opdivo


opdivo use: nivolumab

7,586

Search details

Summary:

[drug]/[subheading] OR [drug]-induced:de,ab,ti

 Full search strategy

Show 1,392 results >

Next step >

Embase的专门检索表单PV Wizard

EMA's MLM search

Drug name

Alternative drug names

Adverse drug reactions

Special situations

ALL

Nivolumab:de OR **+ 8 variants**

8 variants for Nivolumab from Emtree have been added to your search (see the panel on the left)

+ Add more alternative drug names [Reset form](#)

Search in:

:tn Tradename

:tn,tl Tradename or title

:tn,tl,ab **Tradename, title or abstract**

:all All fields

Search details

Summary:

[drug]/[subheading] OR [drug]-induced:de,ab,
[drug]:de OR [variants]:tn,tl,ab

[Full search strategy](#)

< Previous step

Show 7,833 results >

Next >

Embase的专门检索表单PV Wizard

[EMA's MLM searches >](#)

Drug name

Alternative drug names

Adverse drug reactions

Special situations

Human limit

```
'adverse drug reaction'/exp OR 'adverse drug reaction':lnk OR adverse:de,ab,ti OR ((side OR undesirable OR unwanted) NEXT/2 (effect* OR reaction* OR event* OR outcome*)):de,ab,ti OR 'side effect'/lnk OR 'side effect'/exp OR 'complication'/lnk OR 'complication'/exp OR complication*:de,ab,ti OR 'worsening':de,ab,ti OR 'case report*':de,ab,ti OR 'pharmacovigilance':de,ab,ti OR 'postmarketing surveillance'/exp OR 'drug interaction':lnk OR 'drug interaction'/exp OR 'toxicity'/exp OR 'drug toxicity':lnk OR toxic*:de,ab,ti OR Intox*:de,ab,ti OR 'safety':de,ab,ti OR poison*:de,ab,ti OR pharmacotox*:de,ab,ti OR neurotox*:de,ab,ti OR cardiotox*:de,ab,ti OR nephrotox*:de,ab,ti OR hepatotox*:de,ab,ti OR Immunotox*:de,ab,ti OR Immunocytotox*:de,ab,ti OR cytotox*:de,ab,ti OR carcinogen*:de,ab,ti OR cancerogen*:de,ab,ti OR mutagen*:de,ab,ti OR terato*:de,ab,ti OR 'fatal outcome'/exp OR 'death'/exp OR death*:de,ab,ti OR 'suicide'/exp OR suicid*:de,ab,ti OR mortal*:de,ab,ti OR fatal*:de,ab,ti OR 'risk'/exp OR nocebo:de,ab,ti OR 'lethal concentration'/exp OR 'iatrogenic disease'/exp OR 'fertility'/exp OR 'substance-related disorders'/exp OR 'chemically induced':de,ab,ti OR 'morbidity':de,ab,ti OR 'congenital disorder':de,ab,ti OR Infertility/exp OR Injury/exp
```

预设检索策略

[Clear query](#) [Reset form](#)
[Update >](#)

Search details

Summary:

```
(([drug]/[subheading] OR [drug]-induced:de,ab,ti) OR ([drug]:de OR [variants]:tn,ti,ab) AND ([adverse drug reactions]))
```

[Full search strategy](#)
[< Previous step](#)
[Show 6,727 results >](#)
[Next step >](#)

Embase的专门检索表单PV Wizard

[EMA's MLM searches >](#)


```
'pregnancy'/exp OR pregnant*:de,ab,ti OR pregnanc*:de,ab,ti OR 'pregnancy complication'/exp OR 'pregnancy disorder'/exp OR 'abortion'/exp OR 'abortion':de,ab,ti OR 'lactation'/exp OR 'breast feeding':de,ab,ti OR 'breastfeeding':de,ab,ti OR 'breast milk':de,ab,ti OR 'reproduction'/de OR 'fetus'/de OR 'embryo'/de OR 'prenatal':de,ab,ti OR 'perinatal':de,ab,ti OR 'newborn':de,ab,ti OR 'parameters concerning the fetus, newborn and pregnancy'/exp OR aged/exp OR elderly:de,ti,ab OR geriatric*:ti,ab OR ((environmental OR occupational) NEXT/1 exposure*):de,ab,ti OR 'compassionate use':de,ab,ti OR (named NEXT/1 (use OR patient*)):ab,ti OR 'inappropriate prescri*':de,ab,ti OR 'drug metabolism'/exp OR 'organ dysfunction':de,ab,ti OR 'organ failure':de,ab,ti OR 'hypersensitivit*':de,ab,ti OR allerg*:de,ab,ti OR counterfeit:de,ab,ti OR 'falsified drug':de,ab,ti OR ('unavallab*' NEAR/2 drug):de,ab,ti OR 'drug resistance'/exp OR 'drug resistance':de,ab,ti OR 'withdrawal syndrome'/de OR (drug* NEAR/3 (withdrawal OR toleran* OR interact* OR exposure* OR induc* OR resist* OR ineff* OR nonrespon* OR unrespon*)):de,ab,ti OR 'drug tolerance'/exp OR ((drug* OR treatment) NEXT/1 (failure* OR contraindication*)):de,ab,ti OR 'medication error'/exp OR (near NEXT/1 miss*):ab,ti OR ineff*:ti OR nonrespon*:ti OR unrespon*:ti OR ((lack OR no OR non OR 'not') NEXT/2 (eff* OR respon*)):ab,ti OR 'device failure':de,ab,ti OR manufacturing near/3 (error OR fault OR mistake OR failure OR contamination OR impurity) OR 'patient compliance'/exp OR overdos*:de,ab,ti OR 'drug abuse'/exp OR abus*:de,ab,ti OR misus*:de,ab,ti OR 'off label':de,ab,ti OR unlicensed:de,ab,ti
```

预设检索策略: including the use of a medicinal product during pregnancy or breastfeeding, in a paediatric or elderly population, lack of therapeutic efficacy, overdose, abuse, misuse, medication error or occupational exposure...

Search details

Summary:

```
(([drug]/[subheading] OR [drug]-Induced:de,ab,ti) OR ( ([drug]:de OR [variants]:tn,ti,ab) AND ( ([adverse drug reactions]) OR ([special situations]) ) ) )
```

[Previous step](#)
[Show 6,953 results >](#)
[Next step >](#)

Embase的专门检索表单PV Wizard

[EMA's MLM searches >](#)

[Drug name](#)
[Alternative drug names](#)
[Adverse drug reactions](#)
[Special situations](#)
Human limit

human'/exp OR human OR m?n OR wom?n OR child OR boy OR girl

[Clear query](#)
[Reset form](#)

Limit to:

Publication years (including):
 Records added to Embase (including end date):

2018 to 2018
1-1-2016 to 31-12-2016

Search details

Summary:

```

([drug]/[subheading] OR [drug]-Induced:de,ab,ti)
OR ( ([drug]:de OR [variants]:tn,ti,ab) AND (
([adverse drug reactions]) OR ([special situations]) ) )
) AND (human limit)
          
```

[Full search strategy](#)

[< Previous step](#)
Show 6,833 results >
No new notifications

Embase的专门检索表单PV Wizard

Results

umab/exp/'adverse drug reaction','drug toxicity','drug interaction' OR 'nivolumab-induced':de,ab,ti OR (('nivolumab':de OR 'bms 936558':tn,ti,ab OR 'bms936558':tn,ti,ab OR 'mdx 1106':tn,ti,ab OR 'mdx1106':tn,ti,ab OR 'nivolumab':tn,ti,ab OR 'ono 4538':tn,ti,ab OR 'ono4538':tn,ti,ab OR 'odivo':tn,ti,ab) AND ('adverse drug reaction'/exp OR 'adverse drug reaction':lnk OR adverse:de,ab,ti OR (((side OR undesirable OR unwanted) NEXT/2 (effect* OR reaction* OR event* OR outcome*)):de,ab,ti) OR 'side effect':lnk OR 'side effect'/exp OR 'complication':lnk OR 'complication'/exp OR 'complication':de,ab,ti OR 'worsening':de,ab,ti OR 'case report*':de,ab,ti OR 'pharmacovigilance':de,ab,ti OR 'postmarketing surveillance'/exp OR 'drug interaction':lnk OR 'drug interaction'/exp OR 'toxicity'/exp OR 'drug toxicity':lnk OR toxic*:de,ab,ti OR 'adverse':de,ab,ti OR 'safety':de,ab,ti OR 'poison*':de,ab,ti OR 'pharmacotox*':de,ab,ti OR 'neurotox*':de,ab,ti OR 'cardiotox*':de,ab,ti OR 'nephrotox*':de,ab,ti OR 'hepatotox*':de,ab,ti OR 'immunotox*':de,ab,ti OR 'immunocytotox*':de,ab,ti OR 'cytotox*':de,ab,ti OR 'cardinogen*':de,ab,ti OR 'mutagen*':de,ab,ti OR 'terato*':de,ab,ti OR 'fatal outcome'/exp OR 'death'/exp OR death*:de,ab,ti OR 'suicide'/exp OR suicid*:de,ab,ti OR 'mortal*':de,ab,ti OR 'fatal*':de,ab,ti OR 'risk'/exp OR 'nocebo':de,ab,ti OR 'lethal concentration'/exp OR 'iatrogenic disease'/exp OR 'infertility'/exp OR 'substance-related disorders'/exp OR 'chemically induced':de,ab,ti OR 'morbidity':de,ab,ti OR 'congenital disorder':de,ab,ti OR 'infertility'/exp OR 'injury'/exp OR 'pregnancy'/exp OR 'pregnant*':de,ab,ti OR 'pregnanc*':de,ab,ti OR 'pregnancy complication'/exp OR 'pregnancy disorder'/exp OR 'abortion'/exp OR 'abortion':de,ab,ti OR 'lactation'/exp OR 'breast feeding':de,ab,ti OR 'breastfeeding':de,ab,ti OR 'breast milk':de,ab,ti OR 'reproduction'/de OR 'fetus'/de OR 'embryo'/de OR 'prenatal':de,ab,ti OR 'perinatal':de,ab,ti OR 'newborn':de,ab,ti OR 'parameters concerning the fetus, newborn and pregnancy'/exp OR 'aged'/exp OR 'elderly':de,ti,ab OR 'geriatric*':ti,ab OR (((environmental OR occupational) NEXT/1 exposure*):de,ab,ti) OR 'compassionate use':de,ab,ti OR ((named NEXT/1 (use OR patient*)):ab,ti) OR 'inappropriate use':de,ab,ti OR 'drug metabolism'/exp OR 'organ dysfunction':de,ab,ti OR 'organ failure':de,ab,ti OR 'hypersensitivity*':de,ab,ti OR 'allerg*':de,ab,ti OR 'counterfeit':de,ab,ti OR 'falsified drug':de,ab,ti OR (('unavailab*' NEAR/2 drug):de,ab,ti) OR 'drug resistance'/exp OR 'drug resistance':de,ab,ti OR 'withdrawal syndrome'/de OR ((drug* NEAR/3 (withdrawal OR toleran* OR interact* OR exposure* OR induc* OR resist* OR ineff* OR nonrespon* OR unrespon*)):de,ab,ti) OR 'drug tolerance'/exp OR (((drug* OR treatment) NEXT/1 (failure* OR indication*)):de,ab,ti) OR 'medication error'/exp OR ((near NEXT/1 miss*):ab,ti) OR ineff*:ti OR nonrespon*:ti OR unrespon*:ti OR (((lack OR no OR non OR 'not') NEXT/2 (eff* OR respon*)):ab,ti) OR 'device failure':de,ab,ti OR (manufacturing NEAR/3 (error OR fault OR mistake OR contamination OR impurity)) OR 'patient compliance'/exp OR overdos*:de,ab,ti OR 'drug abuse'/exp OR abus*:de,ab,ti OR misus*:de,ab,ti OR 'off label':de,ab,ti OR 'unlicensed':de,ab,ti))) AND ('human'/exp OR human OR m?n OR wom?n OR child OR boy OR girl)

ch > Mapping Date Sources Fields Quick limits EBM Pub. types Languages Gender Age Animal Search

Results Filters

- Expand Collapse all Apply
- Sources
- GS
- ases
- ices
- ating Subheadings
- der
- dy types

History

6,833 results for search #1 Set email alert Set RSS feed Search details Index miner

Results View | Print | Export | Email | Order | Add to Clipboard 1 — 25

Select number of items Selected: 0 (clear) Show all abstracts Sort by: Relevance Publication Year Entry Date

- 1 Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment: A Case Report
Occhipinti M., Falcone R., Onesti C.E., Marchetti P.
Drug Safety - Case Reports 2018 5:1 Article Number 12
Embase Abstract Index Terms View Full Text Similar records
- 2 Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs
Maeda H., Khatami M.
Clinical and Translational Medicine 2018 7:1 Article Number 11
Embase Abstract Index Terms View Full Text Similar records

保存检索结果，并设立定期Email Alert

Results

umab/exp/'adverse drug reaction','drug toxicity','drug interaction' OR 'nivolumab-induced':de,ab,ti OR (('nivolumab':de OR 'bms 936558':tn,ti,ab OR 'bms936558':tn,ti,ab OR 'mdx 1106':tn,ti,ab OR 'mdx1106':tn,ti,ab OR 'nivolumab':tn,ti,ab OR 'ono 4538':tn,ti,ab OR 'ono4538':tn,ti,ab) AND ('adverse drug reaction'/exp OR 'adverse drug reaction'/link OR adverse:de,ab,ti OR (((side OR undesirable OR unwanted) NEXT/2 (effect* OR reaction* OR event* OR outcome*)):de,ab,ti) OR 'side effect'/link OR 'side effect'/exp OR 'complication'/link OR 'complication'/exp OR complication*:de,ab,ti OR 'worsening':de,ab,ti OR 'case report*':de,ab,ti OR 'pharmacovigilance':de,ab,ti OR 'postmarketing surveillance'/exp OR 'drug interaction':link OR 'drug interaction'/exp OR 'toxicity'/exp OR 'drug toxicity':link OR toxic*:de,ab,ti OR 'adverse':de,ab,ti OR 'safety':de,ab,ti OR 'poison*':de,ab,ti OR 'pharmacotox*':de,ab,ti OR 'neurotox*':de,ab,ti OR 'cardiotox*':de,ab,ti OR 'nephrotox*':de,ab,ti OR 'hepatotox*':de,ab,ti OR 'immunotox*':de,ab,ti OR 'immunocytotox*':de,ab,ti OR 'cytotox*':de,ab,ti OR 'cardinogen*':de,ab,ti OR 'mutagen*':de,ab,ti OR 'terato*':de,ab,ti OR 'fatal outcome'/exp OR 'death'/exp OR death*:de,ab,ti OR 'suicide'/exp OR suicid*:de,ab,ti OR 'mortal*':de,ab,ti OR 'fatal*':de,ab,ti OR 'risk'/exp OR 'nocebo':de,ab,ti OR 'lethal concentration'/exp OR 'iatrogenic disease'/exp OR 'fertility'/exp OR 'substance-related disorders'/exp OR 'chemically induced':de,ab,ti OR 'morbidity':de,ab,ti OR 'congenital disorder':de,ab,ti OR 'infertility'/exp OR 'injury'/exp OR 'pregnancy'/exp OR pregnant*:de,ab,ti OR 'pregnanc*':de,ab,ti OR 'pregnancy complication'/exp OR 'pregnancy disorder'/exp OR 'abortion'/exp OR 'abortion':de,ab,ti OR 'lactation'/exp OR 'breast feeding':de,ab,ti OR 'breastfeeding':de,ab,ti OR 'breast milk':de,ab,ti OR 'reproduction'/de OR 'fetus'/de OR 'embryo'/de OR 'prenatal':de,ab,ti OR 'perinatal':de,ab,ti OR 'newborn':de,ab,ti OR 'parameters concerning the fetus, newborn and pregnancy'/exp OR 'aged'/exp OR elderly:de,ti,ab OR geriatric*:ti,ab OR (((environmental OR occupational) NEXT/1 exposure*):de,ab,ti) OR 'compassionate use':de,ab,ti OR ((named NEXT/1 (use OR patient*)):ab,ti) OR 'inappropriate use':de,ab,ti OR 'drug metabolism'/exp OR 'organ dysfunction':de,ab,ti OR 'organ failure':de,ab,ti OR 'hypersensititv*':de,ab,ti OR 'allerg*':de,ab,ti OR 'counterfeit':de,ab,ti OR 'falsified drug':de,ab,ti OR (('unavailab*' NEAR/2 drug*:de,ab,ti) OR 'drug resistance'/exp OR 'drug resistance':de,ab,ti OR 'withdrawal syndrome'/de OR ((drug* NEAR/3 (withdrawal OR toleran* OR interact* OR exposure* OR induc* OR resist* OR ineff* OR nonrespon* OR unrespon*)):de,ab,ti) OR 'drug tolerance'/exp OR (((drug* OR treatment) NEXT/1 (failure* OR indication*)):de,ab,ti) OR 'medication error'/exp OR ((near NEXT/1 miss*):ab,ti) OR ineff*:ti OR nonrespon*:ti OR unrespon*:ti OR (((lack OR no OR non OR 'not') NEXT/2 (eff* OR contamination OR impurity))) OR 'patient compliance'/exp OR overdos*:de,ab,ti OR 'drug abuse'/exp OR abus*:de,ab,ti OR 'misus*':de,ab,ti OR 'off label':de,ab,ti OR 'unlabeled':de,ab,ti

ch > Mapping Date Sources Fields Quick limits EBM Pub. types Languages Gender Age Animal

- Results Filters
- Expand Collapse all Apply
 - Sources
 - Tags
 - Diseases
 - Substances
 - Therapeutic Subheadings
 - Gender
 - Study types

History

6,833 results for search #1 [Set email alert](#) [Set RSS feed](#) [Search details](#) [Index miner](#)

Results View | Print | Export | Email | Order | Add to Clipboard

Select number of items Selected: 0 (clear)

- 1 **Hyperprogressive Disease and Early Hypereosinophilia After Anti-PD-1 Treatment**
Occhipinti M., Falcone R., Onesti C.E., Marchetti P.
Drug Safety - Case Reports 2018 5:1 Article Number 12
Embase Abstract Index Terms View Full Text
- 2 **Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selectivity**
Maeda H., Khatami M.
Clinical and Translational Medicine 2018 7:1 Article Number 11
Embase Abstract Index Terms View Full Text

Set Email Alert

Email alerts will produce an email with a maximum of 500 records.

Alert name

Comments (optional)

Email address(es)

Email addresses should be separated by a semi-colon (;)

Email format HTML Text RIS (as an attachment)

Citations only on

Send an alert only when there are results

Include

- Every day
- Every week
- Every two weeks
- Every month
- Every two months
- Every three months
- Every six months
- Every year

设置每周或每个月等提醒

直接导出搜索组合和结果

Email Alerts

Clipboard Saved Clipboards Email Alerts Saved Searches

Delete | Import | Export alerts

	Last results	Sent on	Status
<input type="checkbox"/> #9 Crizotinib	n/a	not sent yet	<input type="checkbox"/>
<input type="checkbox"/> #8 Fre Edit Copy to advanced search Rerun Send now Export history <input type="checkbox"/> Turn Off			
<input type="checkbox"/> #7 PV Wizard Demo 20170719	300	15 Jan 2018	<input checked="" type="checkbox"/>
<input type="checkbox"/> #6 Embase vs MEDLINE	0	15 Jan 2018	<input checked="" type="checkbox"/>
<input type="checkbox"/> #5 Paracetamol - PV	98	15 Jan 2018	<input checked="" type="checkbox"/>
<input type="checkbox"/> #4 MEDLINE vs EMBASE	0	15 Jan 2018	<input checked="" type="checkbox"/>
<input type="checkbox"/> #3 Daily new	7710	18 Jan 2018	<input checked="" type="checkbox"/>
<input type="checkbox"/> #2 Embase unique	7612	18 Jan 2018	<input checked="" type="checkbox"/>
<input type="checkbox"/> #1 Medline unique articles	0	18 Jan 2018	<input checked="" type="checkbox"/>

Delete | Import | Export alerts

Last results Sent on Status

This is the history of alert "PV alert" as exported on 01 May 2016 19:38 GMT. This alert was originally set up on 22 Dec 2015 10:11 GMT.

Alert name	Event	Search query	Date & time (GMT)	Records in Frequency	Recipients	Status
PV alert	Automatic run	'adverse d:	25.04.2016 03:10	2153 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	18.04.2016 03:10	3446 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	11.04.2016 03:10	1913 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	04.04.2016 03:10	2178 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	28 Mar 2016 03:10	2923 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	21 Mar 2016 03:10	2192 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	14 Mar 2016 03:10	2131 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Send now alert	'adverse d:	08 Mar 2016 15:25	315 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Edited (content sele	'adverse d:	08 Mar 2016 15:25	n/a Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	07 Mar 2016 03:10	3215 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	29.02.2016 03:10	1716 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Edited (disabled)	'adverse d:	22.02.2016 18:46	n/a Every week on Monday	lkrstic@elsevier.com	On
PV alert	Edited (disabled)	'adverse d:	22.02.2016 18:46	n/a Every week on Monday	lkrstic@elsevier.com	Off
PV alert	Send now alert	'adverse d:	22.02.2016 18:43	0 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	22.02.2016 03:10	2383 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	15.02.2016 03:10	3209 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	08.02.2016 03:10	1906 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	01.02.2016 03:10	2871 Every week on Monday	lkrstic@elsevier.com	On
PV alert	Automatic run	'adverse d:	25.01.2016 03:10	1820 Every week on Monday	lkrstic@elsevier.com	On

02341066':tn,ti,ab OR 'pf 1066':tn,ti,ab OR 'pf 2341066':tn,ti,ab OR 'pf02341066':tn,ti,ab OR 'pf1066':tn,ti,ab OR 'pf2341066':tn,ti,ab OR 'xalkori':tn,ti,ab) AND ('adverse drug reaction'/exp OR 'adverse drug reaction':lnk OR adverse:de,ab,ti OR (((side OR undesirable OR unwanted) NEXT/2 (effect* OR reaction* OR event* OR outcome*)):de,ab,ti) OR 'side effect'/lnk OR 'side effect'/exp OR 'complication'/lnk OR 'complication'/exp OR complication*:de,ab,ti OR 'worsening':de,ab,ti OR 'case report*':de,ab,ti OR 'pharmacovigilance':de,ab,ti OR 'postmarketing surveillance'/exp OR 'drug interaction':lnk OR 'drug interaction'/exp OR 'toxicity'/exp OR 'drug toxicity':lnk OR toxic*:de,ab,ti OR intoxic*:de,ab,ti OR 'safety':de,ab,ti OR poison*:de,ab,ti OR pharmacotox*:de,ab,ti OR neurotox*:de,ab,ti OR cardiotox*:de,ab,ti OR nephrotox*:de,ab,ti OR hepatotox*:de,ab,ti OR immunotox*:de,ab,ti OR immunocytotox*:de,ab,ti OR cytotox*:de,ab,ti OR carcinogen*:de,ab,ti OR cancerogen*:de,ab,ti OR mutagen*:de,ab,ti OR terato*:de,ab,ti OR 'fatal outcome'/exp OR 'death'/exp OR death*:de,ab,ti OR 'suicide'/exp OR suicid*:de,ab,ti OR mortal*:de,ab,ti OR fatal*:de,ab,ti OR 'risk'/exp OR nocebo:de,ab,ti OR 'lethal concentration'/exp OR 'iatrogenic disease'/exp OR 'fertility'/exp OR 'substance-related disorders'/exp OR 'chemically induced':de,ab,ti OR 'morbidity':de,ab,ti OR 'congenital disorder':de,ab,ti OR 'infertility'/exp OR 'injury'/exp OR 'pregnancy'/exp OR pregnant*:de,ab,ti OR pregnanc*:de,ab,ti OR 'pregnancy complication'/exp OR 'pregnancy disorder'/exp OR 'abortion'/exp OR 'abortion':de,ab,ti OR 'lactation'/exp OR 'breast feeding':de,ab,ti OR 'breastfeeding':de,ab,ti OR 'breast milk':de,ab,ti OR 'reproduction'/de OR 'fetus'/de OR 'embryo'/de OR 'prenatal':de,ab,ti OR 'perinatal':de,ab,ti OR 'newborn':de,ab,ti OR 'parameters concerning the fetus, newborn and pregnancy'/exp OR 'aged'/exp OR elderly:de,ti,ab OR geriatric*:ti,ab OR (((environmental OR occupational) NEXT/1 exposure*):de,ab,ti) OR

快速查询Opdivo引起的不良反应

The screenshot displays a search interface with several key components:

- Search Bar:** Located at the top right, with navigation links for Search, Entree, Journals, Results, My tools, Register, and Login.
- Filters:** A central column of filters including Drugs, Diseases, Devices, Floating Subheadings, Age, Gender, Study types, Publication types, Journal titles, Publication years, Authors, and Conference Abstracts. The 'Drugs' filter is expanded to show a list of drug categories with counts: nivolumab (6658), ipilimumab (3060), pembrolizumab (3014), programmed death 1 receptor (1934), programmed death 1 ligand 1 (1727), unclassified drug (1244), and endogenous (1207).
- Key subheadings:** A secondary filter menu listing categories like adverse drug reaction (1374), drug combination (955), drug comparison (432), drug interaction (15), and drug therapy (3552).
- Adverse drug reaction:** A dropdown menu showing a list of specific reactions with their respective counts: pneumonia (379), diarrhea (378), fatigue (368), rash (297), colitis (271), pruritus (258), nausea (221), hypothyroidism (210), unspecified side effect (161), side effect (157), hypophysitis (133), decreased appetite (130), fever (122), hepatitis (119), anemia (107), vitiligo (98), hyperthyroidism (96), arthralgia (92), endocrine disease (84), dyspnea (83), and vomiting (74).
- Search Results:** On the right, a list of search results is visible, including titles like 'therapeutic efficacy and unsustainable costs' and 'therapeutic efficacy of cancer immunotherapy', each with a 'Similar records' link.
- Visual Aids:** A Venn diagram on the left shows the overlap between Embase and MEDLINE (2354), MEDLINE only (90), and Embase Classic only (0). Another Venn diagram below it shows the overlap between Embase Classic and MEDLINE (0).

MLM(Medical Literature Monitor)

mbase®

Private Shared **MLM**

EMA's MLM / Plantago /

Back to re

Folder Options

New Edit Delete

- Parietaria
- Paroxetine
- Passiflora
- Pelargonium
- Pentoxifylline
- Perindopril
- Phenylephrine
- Phleum
- Pioglitazone
- Piperacillin
- Piracetam
- Piroxicam
- Plantago**
- Potassium chloride
- Povidone, Iodinated
- Pramipexole
- Pravastatin
- Prednisolone
- Progesterone
- Propanolol Hydrochloride
- Propofol
- Prunus
- Pygeum
- Quercus
- Quetiapine

Plantago

Edit ReRun Delete View Details Set Email Alert Set RSS Feed

<input type="checkbox"/>	Your Query	Name	Last Update	Creation Date	Results
<input type="checkbox"/>	#1	'wässriger auszug mit zucker (1:1) aus 0,7 g plantago lanceolata, folium rec.' OR 'plantaginis lanceolatae folium extractum fluidum' OR 'pressed juice from fresh ribwort plantain herb' OR 'plantago lanceolata' OR 'english plantain' OR 'ribwort plantain' OR 'babka lancetowata' OR 'weegbre' OR 'lancluola' OR 'plantain lanceole' OR 'lantén menor' OR 'spitzwegerich' OR 'wegerich' OR 'tekuty skorocelovy extrakt' OR 'extract fluid de pätlaginä' OR 'plantago seed' OR 'plantain seeds' OR 'ceřteka' OR 'plantaginis lanceolatae folium' OR 'spitzwegerichkraut' OR 'spitzwegerichblätter' OR 'plantaginis ovatae semen' OR 'plantago lanceolatae folium dry extract' OR 'pytek babki' OR 'plantain pollen' OR 'wegerichpollen' OR 'plantain pollen extract' OR 'extrakt aus spitzwegerichpollen' OR 'siauralaply gysloëly lapų skystasis ekstraktas' OR 'fluidextrakt aus spitzwegerichblättern' OR 'aglofibra':tn OR 'agiolax associação':tn OR 'alk-prick n 342 spitzwegerich':tn OR 'allergovit':tn OR 'alyostal':tn OR 'biolid':tn OR 'bioredux abführ-körner':tn OR 'boots natural fibre':tn OR 'bronchi plantago':tn OR 'bronchisan fix':tn OR 'broncho-ser'n':tn OR 'catalet c':tn OR 'c' enat':tn OR 'colofiber':tn OR 'colofibre':tn OR 'depot-hal f.i.t.':tn OR 'dr. theiss husticum':tn OR 'f' emal balans forte':tn OR 'fibrolax complex':tn OR 'flohsamen':tn OR 'flosa':tn OR 'flosema':tn OR 'flosine balance':tn OR 'fybogel':tn OR 'hal allergy prick tests':tn OR 'hal allergy provo spray':tn OR 'husk':tn OR 'husten saft alkohol- und zuckerfrei':tn OR 'husten tropfen bronchial-activ':tn OR 'husten- und erkältungssirup mit spitzwegerich':tn OR 'hustensaft':tn OR 'indische flohsamen':tn OR 'Isogel':tn OR 'ispagel orange':tn OR 'ispaghul g.m.d.':tn OR 'ispaghul rottapharm':tn OR 'ispaghula husk manx':tn OR 'ispaghula husk manx healthcare':tn OR 'ispaghula husk orange manx':tn OR 'laxabene':tn OR 'laxadina':tn OR 'lunelax':tn OR 'mucivital':tn OR 'mucofalk':tn OR 'mucoplant spitzwegerich':tn OR 'mukofalk apfel':tn OR 'mukofalk fit':tn OR 'naturreiner heilpflanzensaft spitzwegerich':tn OR 'neuralgicum oligoplex':tn OR 'pascomucil':tn OR 'pepsa-lax':tn OR 'perosall c':tn OR 'petasites comp.':tn OR 'phostal':tn OR 'plantago k&p diapharm gmbh & c. o. kg':tn OR 'plantago kolkmann diapharm gmbh & co. kg':tn OR 'plantago oligoplex':tn OR 'plantago-homaccord':tn OR 'plantago-primula cum hyoscyamo weleda':tn OR 'plantagotis':tn OR 'plantain pollen':tn OR 'plantasor':tn OR 'plantax':tn OR 'prick test':tn OR 'prick-testlösung wegerich':tn OR 'provokations-testlösung wegerich':tn OR 'psylla':tn OR 'psyllium apotex 900 mg/g':tn OR 'psyllium apotex citroen 581 mg/g':tn OR 'psyllium apotex sinac 581 mg/g':tn OR 'psyllium lan			




车前属类

Embase的专门检索表单PV Wizard



Wizard是国际知名制药公司合
并得到EMA的测试和认可



系统解构搜索组合，化繁为简，帮
助全面检索药物不良反应



一键添加自由词和同义词，系统
供预设的检索组合，加速检索流



感谢您的时间，欢迎批评指正

刘 佳

爱思唯尔生命科学资深解决方案经理

133 0107 0662

e.liu.1@Elsevier.com

2018年11月29日